Baxter gets US nod for intravascular antimicrobial:
This article was originally published in Clinica
A needleless IV connector containing an antimicrobial coating developed by Baxter Healthcare has gained 510(k) clearance from the US FDA. The V-Link Luer-activated device with VitalShield protective coating has been shown to kill 99.9% of pathogens known to cause catheter-related bloodstream infections, including methicillin-resistant Staphylococcus aureus (MRSA). Deerfield, Illinois-based Baxter plans to launch the device in the US in the first half of 2008 and in other markets later in the year.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”